Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + Atezolizumab in Advanced Malignancies
NCT03637764Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2018
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of isatuximab in hepatocellular carcinoma (HCC), squamous cell carcinoma of the head and neck (HNSCC), epithelial ovarian cancer (EOC), glioblastoma (GBM), sponsored by Sanofi. Started Aug 2018; status: terminated.
02
Drugs
isatuximab
03
Conditions
hepatocellular carcinoma (HCC)squamous cell carcinoma of the head and neck (HNSCC)epithelial ovarian cancer (EOC)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03637764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637764.